← Back to Clinical Trials
Recruiting NCT06694051

NCT06694051 Application of Phototherapeutic Keratectomy Mode to Mark the Axis of Astigmatism

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06694051
Status Recruiting
Phase
Sponsor Tianjin Eye Hospital
Condition Astigmatism
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2024-10-01
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
marking

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2024-10-01 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Corneal refractive surgery is an effective way to correct refractive error. Modern corneal refractive surgery for the correction of myopia or hyperopia can achieve or close to the expected goal, but to eliminate astigmatism is always one of the major problems of corneal refractive surgery. The key point in the correction of astigmatism is that as a vector parameter, astigmatism has both magnitude and direction. The angle error may be caused by the rotation of the patient's head position and the involuntary rotation of eyes. Phototherapeutic keratectomy can precisely cut the corneal tissue, and is often used in clinic to remove corneal scars or repair corneal surface morphology. In this study, the excimer laser therapeutic keratectomy mode was used to achieve accurate marking of the axis of astigmatism by setting the treatment laser parameters. With the help of the static cyclotorsion of the eye, the precise treatment of astigmatism could realize.

Eligibility Criteria

Inclusion Criteria: * at least 18 years old Exclusion Criteria: * ocular disease

Contact & Investigator

Central Contact

Wang

✉ jiamei3536@163.com

📞 +86 022 27313336

Frequently Asked Questions

Who can join the NCT06694051 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Astigmatism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06694051 currently recruiting?

Yes, NCT06694051 is actively recruiting participants. Contact the research team at jiamei3536@163.com for enrollment information.

Where is the NCT06694051 trial being conducted?

This trial is being conducted at Tianjin, China.

Who is sponsoring the NCT06694051 clinical trial?

NCT06694051 is sponsored by Tianjin Eye Hospital. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology